Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
2022-09-08 13:01 ET - News Release
PEARL RIVER, N.Y. -- (Business Wire)
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 3 p.m. ET.
The conference will be conducted in a hybrid format, with both in-person and virtual attendees. Acorda's presentation will be streamed only to registered conference attendees, who will be able to view the presentation live, virtually, and on-demand for 30 days through the H.C. Wainwright Conference Platform.
To register for the in-person or virtual conference, please use the following link: https://hcwevents.com/annualconference/
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA(TM) (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS(TM) pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA(TM) (dalfampridine) Extended Release Tablets, 10 mg.